Search

A nanoparticle vaccine designed to fight cancers induced by human papillomavirus (HPV) eradicated tumors in an animal model of late-stage metastatic disease, UT Southwestern Medical Center scientists report in a new study published in PNAS. The findings could ultimately lead to a new type of vaccine

A hormone known for regulating energy balance also helps the body cope with influenza by triggering protective responses in the brain, a study led by UT Southwestern Medical Center researchers shows.

Myron Frederick Weiner, M.D., Professor Emeritus of Psychiatry at UT Southwestern Medical Center and a noted clinical researcher in geriatric psychiatry and Alzheimer’s disease, died July 17 in Dallas. He was 89.

A UT Southwestern Medical Center researcher and his colleagues developed a novel presurgical vaccine strategy that may prevent dangerous infections in patients receiving hip, knee, and other joint replacements.

A new initiative funded by The University of Texas System and the state of Texas seeks to improve care for trauma patients.

At exactly 11 a.m. Friday, surrounded by family, friends, and mentors, 224 members of UT Southwestern Medical School’s Class of 2024 – who all embarked on their medical education during the height of the COVID-19 pandemic – learned where they will continue their medical training.

The holiday season is a time for celebration, but too much celebrating can be bad for your health.

Catherine Spong, M.D., Chair and Professor of Obstetrics and Gynecology at UT Southwestern Medical Center, has been elected to the National Academy of Medicine (NAM) in recognition of her significant impact on the field of maternal-fetal medicine, her leadership in women’s health research, and her

Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).